公开(公告)号：KR101004362B1

公开(公告)日：2010-12-28

申请号：KR1020100024699

申请日：2010-03-19

Applicant: 한국생명공학연구원 ,  가톨릭대학교 산학협력단

Inventor： 박영우 ,  조기원 ,  유석호 ,  유정 ,  김동진 ,  윤선하 ,  송은정 ,  이은경 ,  오진미 ,  조규원 ,  조미라 ,  김호연 ,  박미경 ,  오혜좌 ,  박진실 ,  우윤주

IPC: C07K19/00 ,  C12N15/62 ,  C12N15/63 ,  A61P37/00

CPC classification number: C07K14/525 ,  C07K14/70575 ,  C07K2319/32 ,  Y10S514/814 ,  Y10S514/885 ,  Y10S514/886 ,  Y10S514/903

Abstract: PURPOSE: A TNFR2-TWEAKR fusion protein is provided to ensure antagonistic function to TNFR2 and TWEAK which is a cause of autoimmune arthritis and to reduce IL-17 secretion. CONSTITUTION: A composition for preventing and treating autoimmune disease contains fusion protein of a fragment having an extracellular region of TNFR2(Tumor necrosis factor receptor type 2) or TNFR2 and a fragment having an extracellular region of TWEAKR(TNF-related weak inducer of apoptosis receptor) protein or TWEAKR as an active ingredient. The extracellular region fragment of TNFR2 has a polypeptide having an amino acid sequence of sequence number 2. The fusion protein has an amino acid sequence of sequence number 1.

Abstract translation: 目的：提供TNFR2-TWEAKR融合蛋白，以确保TNFR2和TWEAK的拮抗作用，这是导致自身免疫性关节炎和降低IL-17分泌的原因。 构成：用于预防和治疗自身免疫性疾病的组合物含有具有TNFR2细胞外区域（2型肿瘤坏死因子受体）或TNFR2的片段的融合蛋白和具有TWEAKR胞外区域的片段（TNF相关的凋亡受体弱诱导剂 ）蛋白质或TWEAKR作为活性成分。 TNFR2的细胞外区片段具有序列号为2的氨基酸序列的多肽。融合蛋白具有序列号1的氨基酸序列。

公开(公告)号：KR1020100059374A

公开(公告)日：2010-06-04

申请号：KR1020080118124

申请日：2008-11-26

Applicant: 한국생명공학연구원

Inventor： 박영우 ,  최소영 ,  송은정 ,  유정 ,  손명호 ,  전재원 ,  정준구 ,  장명희 ,  김성섭

IPC: C07K16/18 ,  C07K16/00

CPC classification number: C07K16/22 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/76

Abstract: PURPOSE: A VEGF(vascular endothelial growth factor)-specific human antibody is provided to diagnose and treat VEGF overexpressio-related diseases. CONSTITUTION: A VEFG(vascular endothelial growth factor)-specific human antibody contains a heavy chain with a variable region(VH), or a fragment thereof; and a light chain with a variable region(VL), or a fragment thereof. The heavy chain variable region(VH) contains a heavy chain complementary determining region 1 having an amino acid sequence selected from sequences 5 to 17, HCDR 2 having an amino acid sequence selected from sequence numbers 18-30, and HCDR 3 having an amino acid sequence selected from sequence numbers 31-43. A pharmaceutical composition for preventing and treating VEGF overexpression-related diseases contains VEFG-specific human antibody.

Abstract translation: 目的：提供VEGF（血管内皮生长因子）特异性人抗体来诊断和治疗VEGF过表达相关疾病。 构成：VEFG（血管内皮生长因子）特异性人抗体含有具有可变区（VH）或其片段的重链; 和具有可变区（VL）的轻链或其片段。 重链可变区（VH）包含具有选自序列5至17的氨基酸序列的重链互补决定区1，具有选自序列号18-30的氨基酸序列的HCDR 2和具有氨基酸的HCDR 3 顺序选自序列号31-43。 用于预防和治疗VEGF过表达相关疾病的药物组合物含有VEFG特异性人抗体。

公开(公告)号：KR101473328B1

公开(公告)日：2014-12-16

申请号：KR1020090037838

申请日：2009-04-29

Applicant: 한국생명공학연구원 ,  주식회사 엔지노믹스

Inventor： 박영우 ,  최소영 ,  송은정 ,  조기원 ,  김성섭 ,  장명희 ,  류기혁 ,  김진숙 ,  박소연 ,  이경민 ,  이미혜

IPC: C07K16/18 ,  A61K39/395 ,  A61P35/00 ,  A61K51/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/21

Abstract: 본발명은사이토케라틴17(Cytokeratin17)-특이적인인간항체에관한것으로, 구체적으로사이토케라틴17에특이적으로결합하는인간으로부터유도된상보성결정영역(complementarity determining region, CDR)과프레임워크영역(framework region, FR)으로구성된인간항체에관한것이다. 본발명의사이토케라틴17에특이적인인간항체는상기사이토케라틴17이과발현되는암질환의진단, 질환의분류, 영상화, 치료및 예후판정등에이용될수 있다.

公开(公告)号：KR101004363B1

公开(公告)日：2010-12-28

申请号：KR1020100024700

申请日：2010-03-19

Applicant: 한국생명공학연구원 ,  가톨릭대학교 산학협력단

Inventor： 박영우 ,  조기원 ,  유석호 ,  유정 ,  윤선하 ,  박지현 ,  송은정 ,  이종호 ,  서민지 ,  조선정 ,  조미라 ,  김호연 ,  박미경 ,  오혜좌 ,  박진실 ,  우윤주

IPC: C07K19/00 ,  C12N15/62 ,  C12N15/63 ,  A61P37/00

CPC classification number: C07K14/7151 ,  C07K14/7155 ,  C07K2319/00

Abstract: PURPOSE: A TNFR2-IL21R fusion protein as a double antagonist to TNF-alpha and IL-21 is provided to reduce inflammatory cytokine secretion and to increase anti-inflammatory cytokine secretion. CONSTITUTION: A composition for preventing and treating autoimmune disease contains a fusion protein having a fragment with extracellular region of TNFR2(Tumor necrosis factor receptor type 2) or TNFR2 and a fragment with extracellular region of IL21R(Interleukin-21 receptor) protein or IL21R as an active ingredient. The fusion protein has an amino acid sequence of sequence number 1.

Abstract translation: 目的：提供TNFR2-IL21R融合蛋白作为TNF-α和IL-21的双重拮抗剂，以减少炎症细胞因子分泌和增加抗炎细胞因子分泌。 构成：用于预防和治疗自身免疫疾病的组合物含有具有TNFR2细胞外区域（2型肿瘤坏死因子受体）或TNFR2的片段和IL21R（白细胞介素-21受体）蛋白或IL21R的细胞外区域的片段的融合蛋白，作为 活性成分。 融合蛋白具有序列号1的氨基酸序列。

公开(公告)号：KR1020100042432A

公开(公告)日：2010-04-26

申请号：KR1020080101575

申请日：2008-10-16

Applicant: 한국생명공학연구원

Inventor： 박영우 ,  최소영 ,  장영순 ,  박지현 ,  송은정 ,  유정 ,  손명호 ,  전재원 ,  정준구 ,  김성섭 ,  장명희

IPC: C07K16/18 ,  C07K16/00 ,  C12Q1/68

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C12N9/6424 ,  C07K2317/76 ,  C12N15/63

Abstract: PURPOSE: A TMPRSS4(Transmembrane protease, serine 4)-specific human antibody is provided to use in cancer diagnosis, classification, imaging, treatment and prognosis determination. CONSTITUTION: A human antibody which is specific to TMPRSS4 contains heavy chain with heavy chain variable region(VH) or fraction thereof; and light chain containing the light chain variable region(VL) or fragment thereof. The heavy chain of the heavy chain variable region contains heavy chain complementarity determining region(HCDR 1) of amino acid selected from sequence numbers 7-18, HCDR 2 of amino acid selected from sequence numbers 19-31, or HCDR3 of amino acid selected from sequence numbers 32-44. A pharmaceutical composition for preventing and treating cancer in which TMPRSS4 is overexpressed contains TMPRSS4-specific human antibody.

Abstract translation: 目的：提供TMPRSS4（跨膜蛋白酶，丝氨酸4）特异性人抗体用于癌症诊断，分类，成像，治疗和预后测定。 构成：对TMPRSS4特异性的人抗体含有重链可变区（VH）或其部分的重链; 和含有轻链可变区（VL）或其片段的轻链。 重链可变区的重链含有选自序列号7-18的氨基酸的重链互补决定区（HCDR 1），选自序列号19-31的氨基酸的HCDR 2或选自SEQ ID NO： 序列号32-44。 用于预防和治疗其中TMPRSS4过表达的癌症的药物组合物含有TMPRSS4特异性人抗体。

公开(公告)号：KR100910962B1

公开(公告)日：2009-08-05

申请号：KR1020080092736

申请日：2008-09-22

Applicant: 한국생명공학연구원

Inventor： 박영우 ,  허광래 ,  최소영 ,  박지현 ,  송은정 ,  유정 ,  손명호 ,  김성섭 ,  장명희 ,  김동진

IPC: C07K16/18 ,  C07K16/00

CPC classification number: C07K16/40 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622

Abstract: A human antibody comprising a complementarity determining region (CDR) and framework region (FR) which are induced from a human is provided to use for cancer diagnosis, disease classification, imaging, treatment, and prognosis determination. A human antibody which is specific to ENO1 comprises: a heavy chain CDR (HCDR) 1 which is a polypeptide among sequence numbers 7-12; a polypeptide HCD 2 among the sequence numbers 13-18; a heavy chain having various heavy site (VH) comprising a HCD 3 which is polypeptide among sequence numbers 19-24 and its immunologically active fragment; a light chain CDR 1 which is a polypeptide among sequence numbers 31-36; and a polypeptide LCDR 2 among sequence numbers 37-42.

Abstract translation: 提供了包含由人诱导的互补决定区（CDR）和框架区（FR）的人抗体用于癌症诊断，疾病分类，成像，治疗和预后测定。 对ENO1特异性的人抗体包括：序列号7-12中的多肽的重链CDR（HCDR）1; 序列号13-18中的多肽HCD 2; 具有各种重位点（VH）的重链，其包含序列号19-24中的多肽的HCD 3及其免疫活性片段; 序列号31-36中多肽的轻链CDR1; 和序列号37-42中的多肽LCDR 2。